Arcticzymes Technologies ASA - Asset Resilience Ratio
Arcticzymes Technologies ASA (AZT) has an Asset Resilience Ratio of 20.77% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See AZT net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2025)
This chart shows how Arcticzymes Technologies ASA's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Arcticzymes Technologies ASA total assets.
Liquid Assets Composition Over Time
This chart breaks down Arcticzymes Technologies ASA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read AZT current and long-term liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Nkr0.00 | 0% |
| Short-term Investments | Nkr78.75 Million | 20.77% |
| Total Liquid Assets | Nkr78.75 Million | 20.77% |
Asset Resilience Insights
- Good Liquidity Position: Arcticzymes Technologies ASA maintains a healthy 20.77% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Arcticzymes Technologies ASA Industry Peers by Asset Resilience Ratio
Compare Arcticzymes Technologies ASA's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH |
Biotechnology | 33.23% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
Annual Asset Resilience Ratio for Arcticzymes Technologies ASA (2016–2025)
The table below shows the annual Asset Resilience Ratio data for Arcticzymes Technologies ASA.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 73.25% | Nkr264.72 Million ≈ $27.86 Million |
Nkr361.41 Million ≈ $38.03 Million |
+2.39pp |
| 2024-12-31 | 70.86% | Nkr243.94 Million ≈ $25.67 Million |
Nkr344.26 Million ≈ $36.23 Million |
+17.55pp |
| 2023-12-31 | 53.31% | Nkr180.89 Million ≈ $19.04 Million |
Nkr339.32 Million ≈ $35.71 Million |
-23.22pp |
| 2022-12-31 | 76.53% | Nkr244.16 Million ≈ $25.69 Million |
Nkr319.04 Million ≈ $33.57 Million |
+5.99pp |
| 2021-12-31 | 70.54% | Nkr200.42 Million ≈ $21.09 Million |
Nkr284.11 Million ≈ $29.90 Million |
+7.38pp |
| 2020-12-31 | 63.17% | Nkr140.18 Million ≈ $14.75 Million |
Nkr221.91 Million ≈ $23.35 Million |
+22.85pp |
| 2019-12-31 | 40.32% | Nkr31.29 Million ≈ $3.29 Million |
Nkr77.61 Million ≈ $8.17 Million |
-6.24pp |
| 2018-12-31 | 46.55% | Nkr31.66 Million ≈ $3.33 Million |
Nkr68.02 Million ≈ $7.16 Million |
-3.05pp |
| 2017-12-31 | 49.60% | Nkr30.59 Million ≈ $3.22 Million |
Nkr61.68 Million ≈ $6.49 Million |
-17.60pp |
| 2016-12-31 | 67.19% | Nkr57.67 Million ≈ $6.07 Million |
Nkr85.83 Million ≈ $9.03 Million |
-- |
About Arcticzymes Technologies ASA
ArcticZymes Technologies ASA, a life sciences company, develops, manufactures, and commercializes recombinant enzymes for use in molecular research, in vitro diagnostics, and biomanufacturing. The company offers shrimp alkaline phosphatase; cod UNG for use in viral and other molecular diagnostic assays for the removal of contaminating dU-DNA; salt active nucleases for the removal of nucleic acids… Read more